“Bimekizumab Clinical Efficacy Responses Translate into Improvements in Patient Outcomes to Week 48 in Patients With Moderate to Severe Hidradenitis Suppurativa: Results from BE HEARD I&II”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s707. Accessed January 23, 2026. https://skin.dermsquared.com/skin/article/view/3859.